Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2153-2164

  Byrd, J C ^a   Murphy, T ^a   Howard, R S ^a   Lucas, M S ^a   Goodrich, A ^a   Park, K ^a   Pearson, M ^a   Waselenko, J K ^a   Ling, G ^a   Grever, M R ^a   Grillo Lopez, A J ^a   Rosenberg, J ^a   Kunkel, L ^a   Flinn, I W ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; INFUSION; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035871445     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2153     Document Type: Article

References (37)

1. Clinical staging of chronic lymphocytic leukemia
2. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
3. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia
4. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: A CALGB, SWOG, CTG/NCI-C, and ECOG intergroup study
5. Therapy of chronic lymphocytic leukemia: It is time to move onto the next important question
6. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
7. Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
8. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
9. Rituximab for the treatment: Of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
10. Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
11. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
12. Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
13. Cytokine release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with the anti-CD20 monoclonal antibody
14. IDEC-C2B8 anti-CD20 immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response in 48 patients
15. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
16. Monoclonal antibody-based therapies for hematologic malignancies
17. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
18. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia
19. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
20. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
21. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
22. Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2
23. Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage
24. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia
25. Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia
26. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion
27. Infliximab for the treatment of fistulas in patients with Crohn's disease
28. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
29. Rituxan has significant activity in patients with CLL
30. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro
31. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells
32. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
33. Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells independent of complement mediated lysis but requires Fcγ receptor ligation
34. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
35. Herpes virus infections occur frequently following treatment with fludarabine: Results of a prospective natural history study
36. Frequency and type of infections in fludarabine-refractory b-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population
37. Up-regulation of CD20 expression in chronic lymphocytic leukemia cells by in vitro exposure to cytokines